Drug Profile
Voclosporin - Aurinia Pharmaceuticals
Alternative Names: trans-ISA 247; trans-R 1524; ISA(TX)247; ISA-247; ISAtx 247; ISATx247; LUPKYNIS; Orelvo; R-1524; VocleraLatest Information Update: 20 Nov 2023
Price :
$50
*
At a glance
- Originator Isotechnika
- Developer Atrium Medical Corporation; Aurinia Pharmaceuticals; Isotechnika; Leiden University Medical Center; Otsuka Pharmaceutical; Paladin Labs
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Antivirals; Ciclosporins; Eye disorder therapies; Immunotherapies; Skin disorder therapies; Small molecules; Urologics; Vascular disorder therapies
- Mechanism of Action Calcineurin inhibitors; Immunosuppressants; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Lupus nephritis
- Phase II COVID 2019 infections; Focal segmental glomerulosclerosis
- No development reported Nephrotic syndrome; Renal transplant rejection
- Discontinued Coronary artery restenosis; Plaque psoriasis; Rheumatoid arthritis
Most Recent Events
- 13 Nov 2023 Preregistration for Lupus nephritis (Adjunctive treatment) in Japan (PO)
- 13 Nov 2023 Aurinia Pharmaceuticals expects regulatory submission to the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan in the second half of 2023
- 10 Nov 2023 Updated efficacy data from a phase III AURORA 1 trial in Lupus nephritis presented at the ACR Convergence 2023